Washington Oregon Biotech Networks | Seattle, Portland and regional news, jobs, and events

  • Home
  • About
  • News
    • All News
    • Trending News & Jobs
  • Jobs
    • All Jobs
    • Featured Jobs
    • Post a Job
  • Subscribe
  • Contact
News Ticker
  • [ September 29, 2023 ] Oregon House Republicans propose bills to repeal Measure 110 drug decriminalization News
  • [ September 29, 2023 ] Health research funding to Oregon slowed in 2022 News
  • [ September 29, 2023 ] Legacy doctors and nurse practitioners file for union recognition News
  • [ September 29, 2023 ] Exclusive: Former Genentech duo reunites to push Sonoma into the clinic; Ex-Magenta commercial chief heads to Editas News
  • [ September 29, 2023 ] Sonoma Biotherapeutics Appoints Joseph R. Arron, M.D., Ph.D., as Chief Scientific Officer and Mark D. Eisner, M.D., MPH, as Chief Medical Officer News
HomeNewsWhat CytoDyn leaders are saying as their stock tumbles

What CytoDyn leaders are saying as their stock tumbles

March 31, 2022 WOBN News Comments Off on What CytoDyn leaders are saying as their stock tumbles

The company is seeking partnerships while two drug programs are on hold.
Click here to view original post

Previous

Leader of a large independent Portland medical practice to retire

Next

Aridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business Update

Follow/Subscribe

WOBN Jobs

POST A JOB

WOBN Featured Jobs

  • Field Application Scientist, SF Bay & Oregon | NanoString | Remote SF Bay/Oregon
    August 29, 2023 0

Tweets by WOBionetwork


Advertise With Biotech Networks

Copyright © 2023 Biotech Networks, LLC

Get Biotech Networks Briefs in Your Inbox: Trending News & Featured Jobs